EGFR and neoplasm: Most current anti-EGFR therapies have poor BBB-penetrance, and thus their limited effectiveness may be due in part to insufficient drug delivery.6,29 Previous studies have shown that the BBB can prevent drug levels in the brain from reaching the requisite concentration for tumor killing.30 The present study sought to overcome this challenge by using a more BBB-penetrant EGFR inhibitor.